Company Description
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States.
The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 20, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Andrew Cheng |
Contact Details
Address: 601 Gateway Boulevard, Suite 350 South San Francisco, California 94080 United States | |
| Phone | 650 487 6488 |
| Website | akerotx.com |
Stock Details
| Ticker Symbol | AKRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001744659 |
| CUSIP Number | 00973Y108 |
| ISIN Number | US00973Y1082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive Vice President, Chief Operating Officer and Secretary |
| Dr. Timothy Rolph Ph.D. | Co-Founder and Chief Scientific Officer |
| William R. White J.D. | Executive Vice President, Chief Financial Officer, Treasurer and Head of Corporate Development |
| Catriona Yale | Executive Vice President and Chief Development Officer |
| Scott A. Gangloff | Chief Technical Officer |
| John J. Schembri | Senior Vice President and Head of Finance |
| Patrick Lamy | Senior Vice President of Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 144 | Filing |
| Dec 10, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 144 | Filing |